Skip to main content
SpringerLink
Log in

Afatinib/rivoceranib

Rash on the face, oral mucositis and hand-foot syndrome: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Ma K, et al. EP1.14-48 Efficacy and Safety of Afatinib Plus Apatinib Combination Therapy for a Lung Adenocarcinoma Patient with Her-2 V659D Mutation. Journal of Thoracic Oncology 14 (Suppl.): S1050 abstr. EP1.14-48, No. 10, Oct 2019. Available from: URL: http://doi.org/10.1016/j.jtho.2019.08.2333 [abstract] - China

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Afatinib/rivoceranib. Reactions Weekly 1778, 19 (2019). https://doi.org/10.1007/s40278-019-70822-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-70822-7

Search

Navigation